AI Stock Analysis - Moderna (MRNA)
Analysis generated December 7, 2025.
Moderna, Inc. is a biotechnology company focused on drug discovery, drug development, and vaccine technologies based on messenger RNA (mRNA). Founded in 2010 and headquartered in Cambridge, Massachusetts, Moderna gained significant recognition and growth potential through its development of the mRNA-based COVID-19 vaccine. The company’s innovation in mRNA technology positions it at a pivotal standpoint for not just the present but also future healthcare solutions.
Stock Alerts - Moderna (MRNA)
 |
Moderna | March 12 Over the past few months, there has been an downward trend in Web Traffic. |
|
Moderna | March 9 Price is up by 7.3% in the last 24h. |
|
Moderna | March 6 Price is down by -6.9% in the last 24h. |
|
Moderna | March 5 Price is down by -6.9% in the last 24h. |
Download our app to get future alerts delivered in real-time.
Alternative Data for Moderna
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 159 | Sign up | Sign up | Sign up |
| Sentiment | 72 | Sign up | Sign up | Sign up |
| Webpage traffic | 125,000 | Sign up | Sign up | Sign up |
| Employee Rating | 64 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| Patents | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 26 | Sign up | Sign up | Sign up |
| Facebook Followers | 29,692 | Sign up | Sign up | Sign up |
| Reddit Mentions | 7 | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 110 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 110,562 | Sign up | Sign up | Sign up |
| X Followers | 143,500 | Sign up | Sign up | Sign up |
| X Mentions | 44 | Sign up | Sign up | Sign up |
| Youtube Subscribers | 12,200 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| ESG | N/A | Sign up | Sign up | Sign up |
| Lobbying Cost | $143,000 | Sign up | Sign up | Sign up |
| Business Outlook | 28 | Sign up | Sign up | Sign up |
| Linkedin Employees | 6,360 | Sign up | Sign up | Sign up |
About Moderna
Moderna is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts. It focuses on drug discovery, drug development, and vaccine technologies based exclusively on messenger RNA. Moderna's technology platform inserts synthetic nucleoside-modified mRNA into human cells.
| Price | $52.56 |
| Target Price | Sign up |
| Volume | 13,833,885 |
| Market Cap | $20.8B |
| Year Range | $22.36 - $57.8 |
| Dividend Yield | 0% |
| Analyst Rating | 16% buy |
| Industry | Drug Manufacturers |
In the news
 |
Moderna To Pay Up To $2.25B To Settle Patent Suit Over COVID-19 Vaccine TechnologyMarch 5 - MedCity News |
 |
Reddit Traders Are Cheering Moderna While Bears Watch the Cash BurnMarch 5 - 24/7 Wall St. |
Moderna Settles a Covid Vaccine Patent Lawsuit. What It Means for the Stock. - Barron'sMarch 4 - Slashdot.org |
|
 |
Moderna Settles with Genevant and Arbutus, Ending LNP Patent DisputeMarch 4 - IPWatchdog.com |
 |
US Stocks: Moderna rises on $2.25 billion settlement, clearing COVID vaccine patent dispute overhangMarch 4 - The Times of India |
Moderna to pay up to $2.25B to settle COVID vaccine patent matterMarch 4 - Yahoo Entertainment |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q4 '25 | 678M | 452M | 226M | -826M | -790M | -2.110 |
| Q3 '25 | 1.02B | 1.01B | 8M | -200M | -135M | -0.510 |
| Q2 '25 | 142M | 119M | 23M | -825M | -760M | -2.130 |
| Q1 '25 | 107M | 90M | 17M | -971M | -924M | -2.520 |
| Q4 '24 | 956M | 739M | 217M | -1.12B | -1.12B | -2.910 |
Insider Transactions View All
| Klinger Shannon Thyme filed to sell 59,689 shares at $52.3. March 3 '26 |
| Hoge Stephen filed to sell 1,457,427 shares at $48.8. February 25 '26 |
| AFEYAN NOUBAR filed to sell 3,924 shares at $29.5. December 15 '25 |
| Hussain Abbas filed to sell 1,515 shares at $27.6. December 11 '25 |
| Hussain Abbas filed to sell 580 shares at $28. June 12 '25 |
Similar companies
| Company | Price | AI Score | |
|---|---|---|---|
 |
Johnson & JohnsonJNJ |
$241.52 0.2% | 58 |
 |
Eli Lilly and CompanyLLY |
$985.08 0.8% | 62 |
 |
PfizerPFE |
$26.58 1% | 32 |
 |
AstrazenecaAZN |
$189.9 1.4% | 47 |
 |
AbbVieABBV |
$219.68 2.5% | 61 |
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Ro Khanna |
Aug 8, 25 | Buy | $1K - $15K |
| Rob Bresnahan |
Mar 28, 25 | Buy | $1K - $15K |
| Julie Johnson |
Feb 13, 25 | Sell | $1K - $15K |
Read more about Moderna (MRNA) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, youtube subscribers, news mentions, customer reviews, lobbying cost, business outlook & linkedin employees.
FAQ - Moderna
The Market Cap of Moderna is $20.8B.
Currently, the price of one share of Moderna stock is $52.56.
The MRNA stock price chart above provides a comprehensive visual representation of Moderna's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Moderna shares. Our platform offers an up-to-date MRNA stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Moderna (MRNA) does not offer dividends to its shareholders. Investors interested in Moderna should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Moderna are Johnson & Johnson, Eli Lilly and Company, Pfizer, Astrazeneca, and AbbVie.
